Publications by Randi G. Syljuåsen

59 publications found

Publications 2024

1. Ben Diouf O, Gilbert A, Bernay B, Syljuåsen RG, Tudor M, Temelie M, Savu DI, Soumboundou M, Sall C, Chevalier F (2024)
   Phospho-Proteomics Analysis of Early Response to X-Ray Irradiation Reveals Molecular Mechanism Potentially Related to U251 Cell Radioresistance
   Proteomes, 13 (1)
   DOI 10.3390/proteomes13010001, PubMed 39846632
2. Rødland GE, Temelie M, Eek Mariampillai A, Hauge S, Gilbert A, Chevalier F, Savu DI, Syljuåsen RG (2024)
   Potential Benefits of Combining Proton or Carbon Ion Therapy with DNA Damage Repair Inhibitors
   Cells, 13 (12)
   DOI 10.3390/cells13121058, PubMed 38920686
3. Rødland GE, Temelie M, Eek Mariampillai A, Serban AM, Edin NFJ, Malinen E, Lindbergsengen L, Gilbert A, Chevalier F, Savu DI, Syljuåsen RG (2024)
   Interferon signaling is enhanced by ATR inhibition in glioblastoma cells irradiated with X-rays, protons or carbon ions
   Radiother Oncol, 203, 110669
   DOI 10.1016/j.radonc.2024.110669, PubMed 39675575

Publications 2023

1. Bay LTE, Stokke T, Syljuåsen RG, Landsverk HB (2023)
   Analysis of RNA Polymerase II Chromatin Binding by Flow Cytometry
   Bio Protoc, 13 (8), e4659
   DOI 10.21769/BioProtoc.4659, PubMed 37113330
2. Eek Mariampillai A, Hauge S, Kongsrud K, Syljuåsen RG (2023)
   Immunogenic cell death after combined treatment with radiation and ATR inhibitors is dually regulated by apoptotic caspases
   Front Immunol, 14, 1138920
   DOI 10.3389/fimmu.2023.1138920, PubMed 37346039

Publications 2022

1. Bay LTE, Syljuåsen RG, Landsverk HB (2022)
   A novel, rapid and sensitive flow cytometry method reveals degradation of promoter proximal paused RNAPII in the presence and absence of UV
   Nucleic Acids Res, 50 (15), e89
   DOI 10.1093/nar/gkac434, PubMed 35641102
2. Eek Mariampillai A, Hauge S, Øynebråten I, Rødland GE, Corthay A, Syljuåsen RG (2022)
   Caspase activation counteracts interferon signaling after G2 checkpoint abrogation by ATR inhibition in irradiated human cancer cells
   Front Oncol, 12, 981332
   DOI 10.3389/fonc.2022.981332, PubMed 36387237

Publications 2021

1. Hauge S, Eek Mariampillai A, Rødland GE, Bay LTE, Landsverk HB, Syljuåsen RG (2021)
   Expanding roles of cell cycle checkpoint inhibitors in radiation oncology
   Int J Radiat Biol, 99 (6), 941-950
   DOI 10.1080/09553002.2021.1913529, PubMed 33877959
2. Landsverk HB, Sandquist LE, Bay LTE, Syljuåsen RG (2021)
   New link between the RNA polymerase II-CTD and replication stress
   Mol Cell Oncol, 8 (3), 1910008
   DOI 10.1080/23723556.2021.1910008, PubMed 34027044
3. Rødland GE, Hauge S, Hasvold G, Bay LTE, Raabe TTH, Joel M, Syljuåsen RG (2021)
   Differential Effects of Combined ATR/WEE1 Inhibition in Cancer Cells
   Cancers (Basel), 13 (15)
   DOI 10.3390/cancers13153790, PubMed 34359691

Publications 2020

1. Landsverk HB, Sandquist LE, Bay LTE, Steurer B, Campsteijn C, Landsverk OJB, Marteijn JA, Petermann E, Trinkle-Mulcahy L, Syljuåsen RG (2020)
   WDR82/PNUTS-PP1 Prevents Transcription-Replication Conflicts by Promoting RNA Polymerase II Degradation on Chromatin
   Cell Rep, 33 (9), 108469
   DOI 10.1016/j.celrep.2020.108469, PubMed 33264625

Publications 2019

1. Hauge S, Macurek L, Syljuåsen RG (2019)
   p21 limits S phase DNA damage caused by the Wee1 inhibitor MK1775
   Cell Cycle, 18 (8), 834-847
   DOI 10.1080/15384101.2019.1593649, PubMed 30943845
2. Landsverk HB, Sandquist LE, Sridhara SC, Rødland GE, Sabino JC, de Almeida SF, Grallert B, Trinkle-Mulcahy L, Syljuåsen RG (2019)
   Regulation of ATR activity via the RNA polymerase II associated factors CDC73 and PNUTS-PP1
   Nucleic Acids Res, 47 (4), 1797-1813
   DOI 10.1093/nar/gky1233, PubMed 30541148
3. Rødland GE, Melhus K, Generalov R, Gilani S, Bertoni F, Dahle J, Syljuåsen RG, Patzke S (2019)
   The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines
   Front Oncol, 9, 1301
   DOI 10.3389/fonc.2019.01301, PubMed 31850205

Publications 2018

1. Bøe CA, Håland TW, Boye E, Syljuåsen RG, Grallert B (2018)
   A novel role for ATR/Rad3 in G1 phase
   Sci Rep, 8 (1), 6880
   DOI 10.1038/s41598-018-25238-6, PubMed 29720710

Publications 2017

1. Hauge S, Naucke C, Hasvold G, Joel M, Rødland GE, Juzenas P, Stokke T, Syljuåsen RG (2017)
   Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading
   Oncotarget, 8 (7), 10966-10979
   DOI 10.18632/oncotarget.14089, PubMed 28030798
2. Holm KL, Syljuåsen RG, Hasvold G, Alsøe L, Nilsen H, Ivanauskiene K, Collas P, Shaposhnikov S, Collins A, Indrevær RL, Aukrust P, Fevang B, Blomhoff HK (2017)
   TLR9 stimulation of B-cells induces transcription of p53 and prevents spontaneous and irradiation-induced cell death independent of DNA damage responses. Implications for Common variable immunodeficiency
   PLoS One, 12 (10), e0185708
   DOI 10.1371/journal.pone.0185708, PubMed 28973009
3. Li X, Zhong Y, Lu J, Axcrona K, Eide L, Syljuåsen RG, Peng Q, Wang J, Zhang H, Goscinski MA, Kvalheim G, Nesland JM, Suo Z (2017)
   Correction: MtDNA depleted PC3 cells exhibit Warburg effect and cancer stem cell features
   Oncotarget, 8 (4), 7208-7213
   DOI 10.18632/oncotarget.14800, PubMed 28179591

Publications 2016

1. Hasvold G, Lund-Andersen C, Lando M, Patzke S, Hauge S, Suo Z, Lyng H, Syljuåsen RG (2016)
   Hypoxia-induced alterations of G2 checkpoint regulators
   Mol Oncol, 10 (5), 764-73
   DOI 10.1016/j.molonc.2015.12.015, PubMed 26791779
2. Li X, Zhong Y, Lu J, Axcrona K, Eide L, Syljuåsen RG, Peng Q, Wang J, Zhang H, Goscinski MA, Kvalheim G, Nesland JM, Suo Z (2016)
   MtDNA depleted PC3 cells exhibit Warburg effect and cancer stem cell features
   Oncotarget, 7 (26), 40297-40313
   DOI 10.18632/oncotarget.9610, PubMed 27248169

Publications 2015

1. Håland TW, Boye E, Stokke T, Grallert B, Syljuåsen RG (2015)
   Simultaneous measurement of passage through the restriction point and MCM loading in single cells
   Nucleic Acids Res, 43 (22), e150
   DOI 10.1093/nar/gkv744, PubMed 26250117
2. Syljuåsen RG, Hasvold G, Hauge S, Helland Å (2015)
   Targeting lung cancer through inhibition of checkpoint kinases
   Front Genet, 6, 70
   DOI 10.3389/fgene.2015.00070, PubMed 25774168

Publications 2014

1. Halvorsen AR, Helland A, Fleischer T, Haug KM, Grenaker Alnaes GI, Nebdal D, Syljuåsen RG, Touleimat N, Busato F, Tost J, Saetersdal AB, Børresen-Dale AL, Kristensen V, Edvardsen H (2014)
   Differential DNA methylation analysis of breast cancer reveals the impact of immune signaling in radiation therapy
   Int J Cancer, 135 (9), 2085-95
   DOI 10.1002/ijc.28862, PubMed 24658971
2. Lund-Andersen C, Patzke S, Nähse-Kumpf V, Syljuåsen RG (2014)
   PLK1-inhibition can cause radiosensitization or radioresistance dependent on the treatment schedule
   Radiother Oncol, 110 (2), 355-61
   DOI 10.1016/j.radonc.2013.12.014, PubMed 24502970

Publications 2013

1. Hasvold G, Nähse-Kumpf V, Tkacz-Stachowska K, Rofstad EK, Syljuåsen RG (2013)
   The efficacy of CHK1 inhibitors is not altered by hypoxia, but is enhanced after reoxygenation
   Mol Cancer Ther, 12 (5), 705-16
   DOI 10.1158/1535-7163.MCT-12-0879, PubMed 23635654

Publications 2012

1. Beck H, Nähse-Kumpf V, Larsen MS, O'Hanlon KA, Patzke S, Holmberg C, Mejlvang J, Groth A, Nielsen O, Syljuåsen RG, Sørensen CS (2012)
   Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption
   Mol Cell Biol, 32 (20), 4226-36
   DOI 10.1128/MCB.00412-12, PubMed 22907750
2. Halle C, Andersen E, Lando M, Aarnes EK, Hasvold G, Holden M, Syljuåsen RG, Sundfør K, Kristensen GB, Holm R, Malinen E, Lyng H (2012)
   Hypoxia-induced gene expression in chemoradioresistant cervical cancer revealed by dynamic contrast-enhanced MRI
   Cancer Res, 72 (20), 5285-95
   DOI 10.1158/0008-5472.CAN-12-1085, PubMed 22890239

Publications 2011

1. Jørgensen S, Eskildsen M, Fugger K, Hansen L, Larsen MS, Kousholt AN, Syljuåsen RG, Trelle MB, Jensen ON, Helin K, Sørensen CS (2011)
   SET8 is degraded via PCNA-coupled CRL4(CDT2) ubiquitylation in S phase and after UV irradiation
   J Cell Biol, 192 (1), 43-54
   DOI 10.1083/jcb.201009076, PubMed 21220508
2. Küntziger T, Landsverk HB, Collas P, Syljuåsen RG (2011)
   Protein phosphatase 1 regulators in DNA damage signaling
   Cell Cycle, 10 (9), 1356-62
   DOI 10.4161/cc.10.9.15442, PubMed 21451260
3. Menzel T, Nähse-Kumpf V, Kousholt AN, Klein DK, Lund-Andersen C, Lees M, Johansen JV, Syljuåsen RG, Sørensen CS (2011)
   A genetic screen identifies BRCA2 and PALB2 as key regulators of G2 checkpoint maintenance
   EMBO Rep, 12 (7), 705-12
   DOI 10.1038/embor.2011.99, PubMed 21637299
4. Sørensen CS, Syljuåsen RG (2011)
   Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication
   Nucleic Acids Res, 40 (2), 477-86
   DOI 10.1093/nar/gkr697, PubMed 21937510
5. Tkacz-Stachowska K, Lund-Andersen C, Velissarou A, Myklebust JH, Stokke T, Syljuåsen RG (2011)
   The amount of DNA damage needed to activate the radiation-induced G2 checkpoint varies between single cells
   Radiother Oncol, 101 (1), 24-7
   DOI 10.1016/j.radonc.2011.05.060, PubMed 21722983

Publications 2010

1. Beck H, Menzel T, Syljuåsen RG, Sørensen CS (2010)
   High-throughput siRNA screens using γH2AX as marker uncover key regulators of genome integrity in mammalian cells
   Cell Cycle, 9 (12), 2257-8
   DOI 10.4161/cc.9.12.12017, PubMed 20699633
2. Beck H, Nähse V, Larsen MS, Groth P, Clancy T, Lees M, Jørgensen M, Helleday T, Syljuåsen RG, Sørensen CS (2010)
   Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase
   J Cell Biol, 188 (5), 629-38
   DOI 10.1083/jcb.200905059, PubMed 20194642
3. Landsverk HB, Mora-Bermúdez F, Landsverk OJ, Hasvold G, Naderi S, Bakke O, Ellenberg J, Collas P, Syljuåsen RG, Küntziger T (2010)
   The protein phosphatase 1 regulator PNUTS is a new component of the DNA damage response
   EMBO Rep, 11 (11), 868-75
   DOI 10.1038/embor.2010.134, PubMed 20890310
4. Petersen L, Hasvold G, Lukas J, Bartek J, Syljuåsen RG (2010)
   p53-dependent G(1) arrest in 1st or 2nd cell cycle may protect human cancer cells from cell death after treatment with ionizing radiation and Chk1 inhibitors
   Cell Prolif, 43 (4), 365-71
   DOI 10.1111/j.1365-2184.2010.00685.x, PubMed 20590661

Publications 2007

1. Syljuåsen RG (2007)
   Checkpoint adaptation in human cells
   Oncogene, 26 (40), 5833-9
   DOI 10.1038/sj.onc.1210402, PubMed 17384683

Publications 2006

1. Syljuåsen RG, Jensen S, Bartek J, Lukas J (2006)
   Adaptation to the ionizing radiation-induced G2 checkpoint occurs in human cells and depends on checkpoint kinase 1 and Polo-like kinase 1 kinases
   Cancer Res, 66 (21), 10253-7
   DOI 10.1158/0008-5472.CAN-06-2144, PubMed 17079442

Publications 2005

1. Syljuåsen RG, Sørensen CS, Hansen LT, Fugger K, Lundin C, Johansson F, Helleday T, Sehested M, Lukas J, Bartek J (2005)
   Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage
   Mol Cell Biol, 25 (9), 3553-62
   DOI 10.1128/MCB.25.9.3553-3562.2005, PubMed 15831461
2. Sørensen CS, Hansen LT, Dziegielewski J, Syljuåsen RG, Lundin C, Bartek J, Helleday T (2005)
   The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair
   Nat Cell Biol, 7 (2), 195-201
   DOI 10.1038/ncb1212, PubMed 15665856

Publications 2004

1. Krämer A, Mailand N, Lukas C, Syljuåsen RG, Wilkinson CJ, Nigg EA, Bartek J, Lukas J (2004)
   Centrosome-associated Chk1 prevents premature activation of cyclin-B-Cdk1 kinase
   Nat Cell Biol, 6 (9), 884-91
   DOI 10.1038/ncb1165, PubMed 15311285
2. Syljuåsen RG, Sørensen CS, Nylandsted J, Lukas C, Lukas J, Bartek J (2004)
   Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing Radiation
   Cancer Res, 64 (24), 9035-40
   DOI 10.1158/0008-5472.CAN-04-2434, PubMed 15604269
3. Sørensen CS, Syljuåsen RG, Lukas J, Bartek J (2004)
   ATR, Claspin and the Rad9-Rad1-Hus1 complex regulate Chk1 and Cdc25A in the absence of DNA damage
   Cell Cycle, 3 (7), 941-5
   PubMed 15190204

Publications 2003

1. Gatei M, Sloper K, Sorensen C, Syljuäsen R, Falck J, Hobson K, Savage K, Lukas J, Zhou BB, Bartek J, Khanna KK (2003)
   Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation
   J Biol Chem, 278 (17), 14806-11
   DOI 10.1074/jbc.M210862200, PubMed 12588868
2. Löffler H, Syljuåsen RG, Bartkova J, Worm J, Lukas J, Bartek J (2003)
   Distinct modes of deregulation of the proto-oncogenic Cdc25A phosphatase in human breast cancer cell lines
   Oncogene, 22 (50), 8063-71
   DOI 10.1038/sj.onc.1206976, PubMed 14603247
3. McBride WH, Iwamoto KS, Syljuasen R, Pervan M, Pajonk F (2003)
   The role of the ubiquitin/proteasome system in cellular responses to radiation
   Oncogene, 22 (37), 5755-73
   DOI 10.1038/sj.onc.1206676, PubMed 12947384
4. Sørensen CS, Syljuåsen RG, Falck J, Schroeder T, Rönnstrand L, Khanna KK, Zhou BB, Bartek J, Lukas J (2003)
   Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A
   Cancer Cell, 3 (3), 247-58
   DOI 10.1016/s1535-6108(03)00048-5, PubMed 12676583

Publications 2001

1. Falck J, Mailand N, Syljuåsen RG, Bartek J, Lukas J (2001)
   The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis
   Nature, 410 (6830), 842-7
   DOI 10.1038/35071124, PubMed 11298456
2. Syljuåsen RG, Krolewski B, Little JB (2001)
   Molecular events in radiation transformation
   Radiat Res, 155 (1 Pt 2), 215-221
   DOI 10.1667/0033-7587(2001)155[0215:meirt]2.0.co;2, PubMed 11121237

Publications 2000

1. Mailand N, Falck J, Lukas C, Syljuâsen RG, Welcker M, Bartek J, Lukas J (2000)
   Rapid destruction of human Cdc25A in response to DNA damage
   Science, 288 (5470), 1425-9
   DOI 10.1126/science.288.5470.1425, PubMed 10827953
2. Whang YE, Tran C, Henderson C, Syljuasen RG, Rozengurt N, McBride WH, Sawyers CL (2000)
   c-Abl is required for development and optimal cell proliferation in the context of p53 deficiency
   Proc Natl Acad Sci U S A, 97 (10), 5486-91
   DOI 10.1073/pnas.97.10.5486, PubMed 10805805

Publications 1999

1. Syljuâsen RG, McBride WH (1999)
   Radiation-induced apoptosis and cell cycle progression in Jurkat T cells
   Radiat Res, 152 (3), 328-31
   PubMed 10453094
2. Syljuåsen RG, Krolewski B, Little JB (1999)
   Loss of normal G1 checkpoint control is an early step in carcinogenesis, independent of p53 status
   Cancer Res, 59 (5), 1008-14
   PubMed 10070956

Publications 1997

1. Chiang CS, Syljuäsen RG, Hong JH, Wallis A, Dougherty GJ, McBride WH (1997)
   Effects of IL-3 gene expression on tumor response to irradiation in vitro and in vivo
   Cancer Res, 57 (18), 3899-903
   PubMed 9307268
2. Syljuåsen RG, Belldegrun A, Tso CL, Withers HR, McBride WH (1997)
   Sensitization of renal carcinoma to radiation using alpha interferon (IFNA) gene transfection
   Radiat Res, 148 (5), 443-8
   PubMed 9355869

Publications 1996

1. McBride WH, Economou JS, Syljuåsen RG, Parrish C, Hackman D, Latham V, Chiang CS, Dougherty GJ (1996)
   The effects of cytokine gene transfer into tumors on host cell infiltration and regression
   Anticancer Res, 16 (3A), 1139-43
   PubMed 8702225
2. Syljuåsen RG, Hong JH, McBride WH (1996)
   Apoptosis and delayed expression of c-jun and c-fos after gamma irradiation of Jurkat T cells
   Radiat Res, 146 (3), 276-82
   PubMed 8752305

Publications 1995

1. McBride WH, Economou JS, Kuber N, Hong JH, Chiang CS, Syljuasen R, Dougherty ST, Dougherty GJ (1995)
   Modification of tumor microenvironment by cytokine gene transfer
   Acta Oncol, 34 (3), 447-51
   DOI 10.3109/02841869509094007, PubMed 7779438

Publications 1992

1. GUSSGARD R, LINDMO T, BREVIK I (1992)
   CALCULATION OF THE TRAPPING FORCE IN A STRONGLY FOCUSED LASER-BEAM
   J. Opt. Soc. Am. B-Opt. Phys., 9 (10), 1922-1930
   DOI 10.1364/JOSAB.9.001922